GEN Exclusives

More »

GEN News Highlights

More »
Jun 15, 2012

FDA Approves GSK’s MenHibrix Meningitis Vaccine

  • FDA approved GlaxoSmithKline’s MenHibrix® (meningococcal groups C and Y and hemophilus b tetanus toxoid conjugate vaccine) for preventing disease caused by Neisseria meningitidis serogroups C and Y and Hemophilus influenzae type b in children aged six weeks to 18 months. The vaccine was developed as to comply with the Centers for Disease Control and Prevention’s recommended immunization schedule for Hib vaccination and to enable vaccination against meningococcal groups C and Y without the need for extra injections.

    The MenHibrix vaccination regime involves administration of four doses given at 2, 4, 6, and 12–15 months of age, although the first dose can be given from six weeks of age and the last at up to 18 months of age. Approval of the vaccine was based on data from international clinical trials involving over 7,500 infants and toddlers.

    Headquartered in Belgium, GSK Vaccines has over 30 approved pediatric and adult products and another 20 in development, both for therapeutic and prophylactic applications. The vaccines business reported turnover of £3.5 billion in 2011, representing 13% of total GSK turnover.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »